Latest filing published 23 Mar 2022 for Oncology Institute, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Scott Dalgleish: trading record in brief
Scott Dalgleish (finance chief) discloses dealings in Starling Oncology, Inc. to SEC (Form 4). The record holds 3 filings, for trades running from 12 November 2021 to 21 March 2022.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 23 March 2022 came the latest disclosure, a share grant in Starling Oncology, Inc. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Scott Dalgleish
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 32,092 shares0Common stockSEC:0001628280-22-007103:0
- 47,566 shares0Common StockSEC:0001104659-21-140226:0
2 of 2 declarations
